Paclitaxel Injection Market

Paclitaxel Injection is a kind of anti-cancer injection taking paclitaxel API as raw material. It is mainly used in breast cancer, ovarian cancer and other cancers.

Paclitaxel injection comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given once every 3 weeks. When paclitaxel injection manufactured with polyoxyethylated castor oil is used to treat Kaposi's sarcoma, it may be given once every 2 or 3 weeks.

Paclitaxel Injection Market contains market size and forecasts of Paclitaxel Injection in global, including the following market information:

Global Paclitaxel Injection Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Paclitaxel Injection Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Paclitaxel Injection companies in 2021 (%)

The global Paclitaxel Injection market was valued at 3482 million in 2021 and is projected to reach US$ 7058.9 million by 2028, at a CAGR of 10.6% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

5ml,30mg Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Paclitaxel Injection include Bristol-Myers Squibb, Celgene Corporation, Hospira, Biological E., Taj Accura, Khandelwal Laboratories, Luye Pharma, Beijing Youcare and Beijing Union, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Paclitaxel Injection manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Paclitaxel Injection Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Paclitaxel Injection Market Segment Percentages, by Type, 2021 (%)

5ml,30mg

10ml,60mg

16.7ml,100mg

25ml,150mg

50ml,300mg

Global Paclitaxel Injection Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Paclitaxel Injection Market Segment Percentages, by Application, 2021 (%)

Ovarian Cancer

Breast Cancer

Cervical Cancer

Pancreatic Cancer

Other

Global Paclitaxel Injection Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Paclitaxel Injection Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Paclitaxel Injection revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Paclitaxel Injection revenues share in global market, 2021 (%)

Key companies Paclitaxel Injection sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Paclitaxel Injection sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Bristol-Myers Squibb

Celgene Corporation

Hospira

Biological E.

Taj Accura

Khandelwal Laboratories

Luye Pharma

Beijing Youcare

Beijing Union

Haiyao

Chuntch